X
RXRX icon

Xponance’s Recursion Pharmaceuticals RXRX Stock Holding History

Xponance’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Buy
41,246
+9,900
+32% +$38.3K ﹤0.01% 1543
2025
Q4 		$128K Buy
31,346
+1,326
+4% +$6.57K ﹤0.01% 1444
2025
Q3 		$146K Buy
30,020
+2,221
+8% +$11.7K ﹤0.01% 1398
2025
Q2 		$141K Buy
27,799
+7,655
+38% +$37.6K ﹤0.01% 1373
2025
Q1 		$107K Buy
20,144
+981
+5% +$7.15K ﹤0.01% 1339
2024
Q4 		$130K Buy
19,163
+3,480
+22% +$23.4K ﹤0.01% 1337
2024
Q3 		$103K Buy
15,683
+2,551
+19% +$18.3K ﹤0.01% 1318
2024
Q2 		$98.5K Buy
+13,132
New +$115K ﹤0.01% 1240

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Xponance's RXRX Position: Q1 2026 in Review

Xponance increased its Recursion Pharmaceuticals (RXRX) stake by 32% in Q1 2026, buying an estimated $38.3K and bringing the position to 41,246 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1543.

Xponance first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $146K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Xponance held 41,246 shares of Recursion Pharmaceuticals worth $127K as of Q1 2026.
  • Xponance bought 9,900 Recursion Pharmaceuticals shares in Q1 2026, an estimated $38.3K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1543 holding.
  • Xponance first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Xponance's Recursion Pharmaceuticals position peaked at $146K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.